Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20030086877 A1
Publication typeApplication
Application numberUS 10/245,705
Publication dateMay 8, 2003
Filing dateSep 18, 2002
Priority dateJul 8, 1992
Also published asUS6673335
Publication number10245705, 245705, US 2003/0086877 A1, US 2003/086877 A1, US 20030086877 A1, US 20030086877A1, US 2003086877 A1, US 2003086877A1, US-A1-20030086877, US-A1-2003086877, US2003/0086877A1, US2003/086877A1, US20030086877 A1, US20030086877A1, US2003086877 A1, US2003086877A1
InventorsRobert Platz, John Patton, Linda Foster, Mohammed Eljamal
Original AssigneePlatz Robert M., Patton John S., Linda Foster, Mohammed Eljamal
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments
US 20030086877 A1
Abstract
According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (%w) water, usually below about 5%w and preferably less than about 3%w; a particle size of about 1.0-5.0 μm mass median diameter (MMD), usually 1.0-4.0 μm MMD, and preferably 1.0-3.0 μm MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%: and an aerosol particle size distribution of about 1.0-5.0 μm mass median aerodynamic diameter (MMAD), usually 1.5-4.5 μm MMAD, and preferably 1.5-4.0 MMAD. Such composition are of pharmaceutical grade purity.
Images(13)
Previous page
Next page
Claims(21)
The subject matter claimed is:
1. A dispersible pharmaceutical-based dry powder composition for pulmonary delivery, said composition comprising a therapeutically effective amount of the pharmaceutical in combination with a pharmaceutically acceptable carrier.
2. The composition of claim 1, wherein the composition is substantially free from penetration enhancers.
3. The composition of claim 2, wherein the carrier comprises HSA.
4. The composition of claim 3, wherein the carrier further comprises a carbohydrate bulking agent.
5. The composition of claim 1, wherein about 95% of the mass of the dry powder composition has a particle size of less than 10 μm.
6. The composition of claim 5, wherein about 80% of the mass of the dry powder composition has a particle size of less than 5μm.
7. A unit dosage form for pulmonary delivery of a pharmaceutical, which dosage form comprises a unit dosage receptacle containing a dispersible pharmaceutical-based dry powder composition which composition comprises a therapeutically effective amount of the pharmaceutical in combination with a pharmaceutically acceptable carrier.
8. The unit dosage form of claim 7 wherein the carrier comprises HSA and a carbohydrate bulking agent, the composition is substantially free from penetration enhancers and about 95% of the mass of the dry powder composition has a particle size of less than about 10 μm.
9. A method of treating a disease state responsive to treatment by a pharmaceutical, which method comprises pulmonarily administering to a subject in need thereof a physiologically effective amount of a dispersible pharmaceutical-based dry powder composition that comprises a therapeutically effective amount of the macromolecule in combination with a pharmaceutically acceptable carrier.
10. The method of claim 9, wherein the carrier comprises HSA and a carbohydrate bulking agent, the composition is substantially free from penetration enhancers and about 95% of the mass of the dry powder composition has a particle size of less than about 10 μm.
11. A method for aerosolizing a pharmaceutical-based dry powder composition that comprises a therapeutically effective amount of the pharmaceutical in combination with a pharmaceutically acceptable carrier, which method comprises:
dispersing an amount of the dry powder composition in a gas stream to form an aerosol and
capturing the aerosol in a chamber suitable for subsequent inhalation by a patient.
12. The method of claim 11, wherein the carrier comprises HSA and a carbohydrate bulking agent, the composition is substantially free from penetration enhancers and about 95% of the mass of the dry powder composition has a particle size of less than about 10 μm.
13. A method for preparing a spray-dried, pharmaceutical-based dry powder composition that comprises a therapeutically effective amount of the macromolecule and a pharmaceutically acceptable carrier, which method comprises spray-drying an aqueous mixture of the macromolecule and the carrier under conditions to provide a respirable dry powder.
14. The method of claim 13 wherein the composition is substantially free from penetration enhancers.
15. The method of claim 14, wherein the carrier comprises HSA.
16. The method of claim 15, wherein the carrier further comprises a carbohydrate bulking agent.
17. The method of claim 16, wherein the bulking agent is mannitol.
18. The method of claim 13, wherein 95% of the mass of the spray-dry composition has a particle size less than 10 μm.
19. A spray-dried, macromolecule-based dry powder composition for pulmonary delivery, said composition comprising a therapeutically effective amount of the macromolecule in combination with a pharmaceutically acceptable carrier that comprises HSA and a carbohydrate bulking agent, wherein the composition is substanually free from penetration enhancers and about 95% of the mass of the dry powder composition has a particle size of less than 10 μm.
20. The composition of claim 19, wherein the bulking agent is mannitol.
21. The composition according to any of claims 1, 7, 9, 13, and 19 wherein the macromolecule is selected from the group comprising insulin, interlukin 1 receptor, parathyroid hormone (PTH-34), alpha-1 antitrypsin, calcitonin, low molecular weight heparin, heparin, interferon, and nucleic acids.
Description
  • [0001]
    This application is a continuation in part of the following U.S. patent applications: Ser. No. 07/910,048. filed Jul. 8, 1992; Ser. No. 08/______ (attorney docket No. 15225-000410), filed Apr. 4, 1995, which is a file wrapper continuation of Ser. No. 08/044,358, filed Apr. 7, 1993; Ser. No. 08/232,849, filed Apr. 25, 1994; Ser. No. 08/309,691, filed Sep. 21, 1994; Ser. No. 08/246,034, filed May 18, 1994; Ser. No. 08/313,707, filed Sep. 27, 1994; and, Ser. No. 08/383,475, filed Feb. 1, 1995, the full disclosures of which are incorporated herein by reference.
  • BACKGROUND OF THE INVENTION
  • [0002]
    1. Field of the Invention
  • [0003]
    The present invention relates generally to methods and compositions for the dry powder formulation of pharmaceuticals, including macromolecules, for pulmonary delivery.
  • [0004]
    Over the years, certain drugs have been sold in compositions suitable for forming a drug dispersion for oral inhalation (pulmonary delivery) to treat various conditions in humans. Such pulmonary drug delivery compositions are designed to be delivered by inhalation by the patient of a drug dispersion so that the active drug within the dispersion can reach the lung. It has been found that certain drugs delivered to the lung are readily absorbed through the alveolar region directly into blood circulation. Pulmonary delivery is particularly promising for the delivery of macromolecules (proteins, polypeptides and nucleic acids) which are difficult to deliver by other routes of administration. Such pulmonary delivery can be effective both for systemic delivery and for localized delivery to treat diseases of the lungs.
  • [0005]
    Pulmonary drug delivery can itself be achieved by different approaches, including liquid nebulizers, aerosol-based metered dose inhalers (MDI's), and dry powder dispersion devices. Aerosol-based MDI's are losing favor because they rely on the use of chlorofluorocarbons (CFC's), which are being banned because of their adverse effect on the ozone layer. Dry powder dispersion devices, which do not rely on CFC aerosol technology, are promising for delivering drugs that may be readily formulated as dry powders. Many otherwise labile macromolecules may be stably stored as lyophilized or spray-dried powders by themselves or in combination with suitable powder carriers. The ability to deliver pharmaceutical compositions as dry powders, however, is problematic in certain respects. The dosage of many pharmaceutical compositions is often critical so it is necessary that any dry powder delivery system be able to accurately, precisely, and reliably deliver the intended amount of drug. Moreover, many pharmaceutical compositions are quite expensive. Thus, the ability to efficiently deliver the dry powders with a minimal loss of drug is critical. It is also essential that the powder be readily dispersible prior to inhalation by the patient in order to assure adequate distribution and systemic absorption.
  • [0006]
    A particularly promising approach for the pulmonary delivery of dry powder drugs utilizes a hand-held device with a hand pump for providing a source of pressurized gas. The pressurized gas is abruptly released through a powder dispersion device, such as a venturi nozzle, and the dispersed powder made available for patient inhalation. While advantageous in many respects, such hand-held devices are problematic in a number of other respects. The particles being delivered are less than 10 μm in size, usually in the range from 1 μm to 5 μm, making powder handling and dispersion more difficult than with larger particles. The problems are exacerbated by the relatively small volumes of pressurized gas, which are available using hand-actuated pumps. In particular, venturi dispersion devices are unsuitable for difficult-to-disperse powders when only small volumes of pressurized gas are available. Another equirement for hand-held and other powder delivery devices is efficiency. It is important that the concentration of drug in the bolus of gas be relatively high to reduce the number of breaths required to achieve a total dosage. The ability to achieve both adequate dispersion and small dispersed volumes is a significant technical challenge that requires in part that each unit dosage of the powdered composition be readily and reliably dispersible.
  • [0007]
    2. Description of the Relevant Literature
  • [0008]
    Dry powder dispersion devices for medicaments are described in a number of patent documents. U.S. Pat. No. 3,921,637 describes a manual pump with needles for piercing through a single capsule of powdered medicine. The use of multiple receptacle disks or strips of medication described in EP467172 (where a reciprocatable punch is used to open a blister pack); WO91/02558; WO93/09832; U.S. Pat. Nos. 4,627,432; 4,811,731; 5,035,237; 5,048,514; 4,446,862; 5,048,514; and 4,446,862. Other patents which show puncturing of single medication capsules include U.S. Pat. Nos. 4,338,931; 3,991,761; 4,249,526; 4,069,819; 4,995,385; 4,889,114; and 4,884,565; and EP469,814, WO90/07351 describes a hand-held pump device with a loose powder reservoir.
  • [0009]
    A dry powder sonic velocity disperser is described in Witham and Gates, Dry Dispersion with Sonic Velocity Nozzles, presented at the workshop on Dissemination Techniques for Smoke and Obscurants, Chemical Systems Laboratory, Aberdeen Proving Ground, Maryland, Mar. 14-16, 1983.
  • [0010]
    U.S. Pat. Nos. 4,926,852 and 4,790,305, describe a type of “spacer” for use with a metered dose inhaler. The spacer defines a large cylindrical volume which receives an axially directed burst of drug from a propellant-driven drug supply. U.S. Pat. No. 5,027,806, is an improvement over the '852 and '305 patents, having a conical holding chamber which receives an axial burst of drug. U.S. Pat. No. 4,624,251, describes a nebulizer connected to a mixing chamber to permit a continuous recycling of gas through the nebulizer. U.S. Pat. No. 4,677,975, is described above. European patent application 347,779 describes an expandable spacer for a metered dose inhaler having a one-way valve on the mouthpiece. WO 90/07351 describes a dry powder oral inhaler having a pressurized gas source (a piston pump) which draws a measured amount of powder into a venturi arrangement.
  • [0011]
    The respiratory delivery of aerosolized aqueous insulin solutions is described in a number of references, beginning with Gänsslen (1925) Klin. Wochenschr. 4:71 and including Laube et al. (1993) JAMA 269:2106-21-9; Elliott et al. (1987) Aust. Paediatr. J. 23:293-297; Wigley et al. (1971) Diabetes 20:552-556. Corthorpe et al. (1992) Pharm Res 9:764-768; Govinda (1959) Indian J. Physiol. Pharmacol. 3:161-167; Hastings et al. (1992) J. Appl. Physiol. 73:1310-1316; Liu et al. (1993) JAMA 269:2106-2109; Nagano et al. (1985) Jikeikai Med. J. 32:503-506; Sakr (1992) Int. J. Phar. 86:1-7; and Yoshida et al. (1987) Clin. Res. 35:160-166. Pulmonary delivery of dry powder medicaments, such as insulin, in a large particle carrier vehicle is described in U.S. Pat. No. 5,254,330. A metered dose inhaler (MDI) for delivering crystalline insulin suspended in a propellant is described in Lee and Sciara (1976) J. Pharm. Sci. 65:567-572. A MDI for delivering insulin into a spacer for regulating inhalation flow rate is described in U.S. Pat. No. 5,320,094. The intrabronchial administration of recombinant insulin is briefly described in Schlüter et al. (Abstract) (1984) Diabetes 33:75A and Köhler et al. (1987) Atemw. Lungenkrkh. 13:230-232. Intranasal and respiratory delivery of a variety of polypeptides, including insulin, in the presence of an enhancer, are described in U.S. Pat. No. 5,011,678 and Nagai et al. (1984) J. Contr. Rel. 1:15-22. Intranasal delivery of insulin in the presence of enhancers and/or contained in controlled release formulations are described in U.S. Pat. Nos. 5,204,108; 4,294,829; and 4,153,689; PCT Applications WO 93/02712, WO 91/02545, WO 90/09780, and WO 88/04556; British Patent 1,527,605; Rydén and Edman (1992) Int. J. Pharm. 83:1-10; and Björk and Edman (1988) Int. J. Pharm. 47:233-238. The preparation and stability of amorphous insulin were described by Rigsbee and Pikal at the American Association of Pharmaceutical Sciences (AAPS), Nov. 14-18, 1993, Lake Buena Vista, Fla. Methods for spray drying polypeptide, polynucleotide and other labile drugs in a carrier which forms an amorphous structure which stabilizes the drug are described in European patent application 520 748. (AAPS), Nov. 14-18, 1993, Lake Buena Vista, Fla.
  • [0012]
    Stribling et al. (1992) J. Biopharm. Sci. 3:255-263, describes the aerosol delivery of plasmids carrying a chloramphenicol acetyltransferase (CAT) reporter gene to mice. The plasmids were incorporated in DOTMA or cholesterol liposomes, and aqueous suspensions of the liposomes were nebulized into a small animal aerosol delivery chamber. Mice breathing the aerosol were found to at least transiently express CAT activity in their lung cells. Rosenfeld et al. (1991) Science: 252:431-434, describes the in vivo delivery of an alpha-1 antitrypsin gene to rats, with secretion of the gene product being observable for at least one week. The gene was diluted in saline and instilled directly into the rat trachea. Friedman (1989) Science 244:1275-1281 is a review article describing human gene therapy strategies.
  • [0013]
    U.S. Pat. Nos. 4,833,125 and 4,698,328, describe the administration of active parathyroid hormone fragments in combination with vitamin D or a dietary calcium supplement. Suggested administration routes include parenteral by injection, rapid infusion, nasopharyngeal absorption, dermal absorption, or oral. See also, Neer et al. (1987) Osteoporosis 53:829-835. U.S. Pat. No. 5,011,678, describes the use of amphophilic steroids as a penetration enhancer for nasal or bronchopulmonary delivery of proteins and polypeptides, listing parathyroid hormone as one of a “veritable host” of proteins which could be delivered with the enhancer. Parathyroid hormone (full length) is secreted naturally from the parathyroid gland as a series of spikes in a pulsatile fashion which is analogous to pituitary hormones (Harms et al. (1987) Int. Symp. on Osteoporosis, Aalborg, Abstract 232). The full length hormone is rapidly broken down in the circulation into several fragments which are the dominant serum forms. It is hypothesized that an intermittent or pulsatile secretion pattern for parathyroid hormone is necessary to maintain its bone restoring properties (Hesch et al. (1988) Calcif. Tissue Int. 42:341-344 and Habener et al. (1971), Proc. Natl. Acad. Sci. USA 68:2986-2991). Patton and Platz (1992) Adv. Drug Deliver. Rev. 8: 179-196, describe methods for delivering proteins and polypeptides by inhalation through the deep lung.
  • [0014]
    The aerosolization of protein therapeutic agents, including alpha-1 antitrypsin, is disclosed in EP0289336. The use of alpha-1 antitrypsin for treating pulmonary inflamnmation is disclosed in U.S. Pat. No. 5,093,316.
  • [0015]
    Therapeutic aerosol formulations, including calcitonin, are disclosed in WO90/09781.
  • [0016]
    Methods and compositions for inhibiting neutrophil elastase and cathespin G employing aerosolized 2-0-desulfated heparin is disclosed in WO94/02107.
  • [0017]
    Interleukin-1 receptor compositions are disclosed in U.S. Pat. Nos. 4,968,607, 5,081,228 and 5,180,812.
  • [0018]
    Aerosol formulations of interferons have been produced for pulmonary delivery as described in WO 91/16038. WO 91/16038 teaches adding a surfactant or the like to improve the dispersibility of a human interferon from a CFC delivery system. Methods and compositions for the preparation of solid polypeptide microparticles as a pharmaceutical aerosol formulation are disclosed in WO 91/16038. The purification of proteins of molecular weight in excess of 12,000, including human IFN is disclosed in U.S. Pat. No.: 4,503,035. Low pH pharmaceutical compositions of recombinant IFN-beta are disclosed in WO 89/05158.
  • [0019]
    3. Objects of the Invention
  • [0020]
    An object of the present invention is to provide a pharmaceutical composition suitable for long-term pulmonary administration to a patient in need thereof.
  • [0021]
    Another object of this invention is to provide a pharmaceutical-containing dispersible dry powdered composition that is administered by inhalation in a manner that is free of a liquid propellant such as a CFC, HFC or carbon dioxide.
  • [0022]
    Another object of this invention is to provide a pharmaceutical-containing dispersible dry powdered composition that can be easily manufactured by a method that maintains a high percentage of pharmaceutical activity.
  • [0023]
    Another object of this invention is to provide a manufacturable method for the production of pharmaceutical composition of sufficient purity.
  • [0024]
    Still another object of this invention is to provide a pharmaceutical-containing dispersible dry powdered composition that exhibits a high level of stability.
  • [0025]
    Other objects may be apparent to one of ordinary skill upon reviewing the following specification and claims.
  • SUMMARY OF THE INVENTION
  • [0026]
    According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (%w) water, usually below about 5%w and preferably less than about 3%w; a particle size of about 1.0-5.0 μm mass median diameter (MMD), usually 1.0-4.0 μm MMD, and preferably 1.0-3.0 μm MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 μm mass median aerodynamic diameter (MMAD), usually 1.5-4.5 μm MMAD, and preferably 1.5-4.0 MMAD. Such composition are of pharmaceutical grade purity.
  • DESCRIPTION OF SPECIFIC EMBODIMENTS
  • [0027]
    The present invention is based at least in part on the dispersibility characteristics of the pharmaceutical-based dry powder compositions produced according to the present invention. The dispersibility characteristics of the subject pharmaceutical-based compositions means that they are more suitable for use in pulmonary delivery devices than compositions prepared by other methods. The compositions of the invention are readily aerosolized and rapidly absorbed through the lungs of a host when delivered by a dry powder inhaler.
  • Definitions
  • [0028]
    In interpreting the claims to the various aspects of this invention, there are several important definitions that should be considered.
  • [0029]
    The term “dispersibility” or “dispersible” means a dry powder having a moisture content of less than about 10% by weight (%w) water, usually below about 5%w and preferably less than about 3%w; a particle size of about 1.0-5.0 μm mass median diameter (MMD), usually 1.0-4.0 μm MMD, and preferably 1.0-3.0 μm MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 μm mass median aerodynamic diameter (MMAD), usually 1.5-4.5 μm MMAD, and preferably 1.5-4.0 μm MMAD. Methods and compositions for improving dispersibility are disclosed in U.S. application Ser. No.: 08/______, filed Apr. 14, 1995 (attorney docket no.: ITSY-003/00US), the disclosures of which are hereby incorporated by reference.
  • [0030]
    The term “powder” means a composition that consists of finely dispersed solid particles that are free flowing and capable of being readily dispersed in an inhalation device and subsequently inhaled by a subject so that the particles reach the lungs to permit penetration into the alveoli. Thus, the powder is said to be “respirable.” Preferably the average particle size is less than about 10 microns (μm) in diameter with a relatively uniform spheroidal shape distribution. More preferably the diameter is less than about 7.5 μm and most preferably less than about 5.0 μm. Usually the particle size distribution is between about 0.1 μm and about 5 μm in diameter, particularly about 0.3 μm to about 5 μm.
  • [0031]
    The term “dry” means that the composition has a moisture content such that the particles are readily dispersible in an inhalation device to form an aerosol. This moisture content is generally below about 10% by weight (%w) water, usually below about 5%w and preferably less than about 3%w.
  • [0032]
    The term “therapeutically effective amount” is the amount present in the composition that is needed to provide the desired level of drug in the subject to be treated to give the anticipated physiological response. This amount is determined for each drug on a case-by-case basis. Guidelines are given hereafter.
  • [0033]
    The term “physiologically effective amount” is that amount delivered to a subject to give the desired palliative or curative effect. This amount is specific for each drug and its ultimate approved dosage level. Guidelines are given hereafter.
  • [0034]
    The term “pharmaceutically acceptable carrier” means that the carrier can be taken into the lungs with no significant adverse toxicological effects on the lungs.
  • Compositions of the Invention
  • [0035]
    One aspect of this invention is a dispersible pharmaceutical-based dry powder composition for pulmonary delivery, the composition comprising a therapeutically effective amount of a pharmaceutical in combination with a pharmaceutically acceptable carrier.
  • [0036]
    In general, the compositions of this invention have a suitable for pulmonary delivery because of their dispersibility characteristics. Such compositions were not previously known in the art. In the dry state, the pharmaceutical may be in crystalline or amorphous form. Pharmaceutical compositions suitable for formulation into dispersible dry powders are listed in Table 1. These include macromolecule and non-macromolecule-based pharmaceuticals, usually macromolecules, with insulin, interleukin-1 receptor, parathyroid hormone (PTH-34), alpha-1 antitrypsin, calcitonin, low molecular weight heparin, heparin, interferon, and nucleic acids being preferred.
  • [0037]
    A therapeutically effective amount of active pharmaceutical will vary in the composition depending on the biological activity of the drug employed and the amount needed in a unit dosage form. Because the subject compounds are dispersible, it is highly preferred that they be manufactured in a unit dosage form in a manner that allows for ready manipulation by the formulator and by the consumer. This generally means that a unit dosage will be between about 0.5 mg and 15 mg of total material in the dry powder composition, preferably between about 2 mg and 10 mg. Generally, the amount of drug in the composition will vary from about 0.05%w to about 99.0%w. Most preferably the composition will be about 0.2% to about 97.0%w drug.
  • [0038]
    The amount of the pharmaceutically acceptable carrier is that amount needed to provide the necessary stability, dispersibility, consistency and bulking characteristics to ensure a uniform pulmonary delivery of the composition to a subject in need thereof. Numerically the amount may be from about 0.05%w to about 99.95%w, depending on the activity of the drug being employed. Preferably about 5%w to about 95%w will be used.
  • [0039]
    The carrier may be one or a combination of two or more pharmaceutical excipients, but will generally be substantially free of any “penetration enhancers.” Penetration enhancers are surface active compounds which promote penetration of a drug through a mucosal membrane or lining and are proposed for use in intranasal, intrarectal, and intravaginal drug formulations. Exemplary penetration enhancers include bile salts, e.g., taurocholate, glycocholate, and deoxycholate; fusidates, e.g., taurodehydrofusidate; and biocompatible detergents, e.g., Tweens, Laureth-9, and the like. The use of penetration enhancers in formulations for the lungs, however, is generally undesirable because the epithelial blood barrier in the lung can be adversely affected by such surface active compounds. The dry powder compositions of the present invention are readily absorbed in the lungs without the need to employ penetration enhancers.
  • [0040]
    The types of pharmaceutical excipients that are useful as carriers in this invention include stabilizers such as human serum albumin (HSA), bulking agents such as carbohydrates, amino acids and polypeptides; pH adjusters or buffers; salts such as sodium chloride; and the like. These carriers may be in a crystalline or amorphous form or may be a mixture of the two.
  • [0041]
    It has been found that HSA is particularly valuable as a carrier in that it provides improved dispersibility.
  • [0042]
    Bulking agents that are particularly valuable include compatible carbohydrates, polypeptides, amino acids or combinations thereof. Suitable carbohydrates include monosaccharides such as galactose, D-mannose, sorbose, and the like; disaccharides, such as lactose, trehalose, and the like; cyclodextrins, such as 2-hydroxypropyl-β-cyclodextrin; and polysaccharides, such as raffinose, maltodextrins, dextrans, and the like; alditols, such as mannitol, xylitol, and the like. A preferred group of carbohydrates includes lactose, threhalose, raffinose maltodextrins, and mannitol. Suitable polypeptides include aspartame. Amino acids include alanine and glycine, with glycine being preferred.
  • [0043]
    Additives, which are minor components of the composition of this invention, may be included for conformational stability during spray drying and for improving dispersibility of the powder. These additives include hydrophobic amino acids such as tryptophan, tyrosine, lucine, phenylalanine, and the like.
  • [0044]
    Suitable pH adjusters or buffers include organic salts prepared from organic acids and bases, such as sodium citrate, sodium ascorbate, and the like; sodium citrate is preferred.
  • [0045]
    The unit dosage form, method of treatment, and process of preparation of this invention are described hereafter.
  • [0046]
    Unit Dosage Form.
  • [0047]
    Another aspect of this invention is a unit dosage form for pulmonary delivery of dispersible dry powder pharmaceutical-based compositions, which dosage form comprises a unit dosage receptacle containing a pharmaceutical-based dry powder composition, which composition comprises a therapeutically effective amount of a pharmaceutical in combination with a pharmaceutically acceptable carrier.
  • [0048]
    In this aspect of the invention, the composition of this invention (as discussed hereinbefore) is placed within a suitable dosage receptacle in an amount sufficient to provide a subject with drug for a unit dosage treatment. The dosage receptacle is one that fits within a suitable inhalation device to allow for the aerosolization of the interferon-based dry powder composition by dispersion into a gas stream to form an aerosol and then capturing the aerosol so produced in a chamber having a mouthpiece attached for subsequent inhalation by a subject in need of treatment. Such a dosage receptacle includes any container enclosing the composition known in the art such as gelatin or plastic capsules with a removable portion that allows a stream of gas (e.g., air) to be directed into the container to disperse the dry powder composition. Such containers are exemplified by those shown in U.S. Pat. No. 4,227,522 issued Oct. 14, 1980; U.S. Pat. No. 4,192,309 issued Mar. 11, 1980; and U.S. Pat. No. 4,105,027 issued Aug. 8, 1978. Suitable containers also include those used in conjunction with Glaxo's Ventolin Rotohaler brand powder inhaler or Fison's Spinhaler brand powder inhaler. Another suitable unit-dose container which provides a superior moisture barrier is formed from an aluminum foil plastic laminate. The pharmaceutical-based powder is filled by weight or by volume into the depression in the formable foil and hermetically sealed with a covering foil-plastic laminate. Such a container for use with a powder inhalation device is described in U.S. Pat. No. 4,778,054 and is used with Glaxo's Diskhaler® (U.S. Pat. Nos. 4,627,432; 4,811,731; and 5,035,237). All of these references are incorporated herein by reference.
  • [0049]
    Method of Treating a Disease State.
  • [0050]
    Another aspect of this invention is a method of treating a condition responsive to treatment by a pharmaceutical of interest, which method comprises pulmonarily administering to a subject in need thereof a physiologically effective amount of a dispersible pharmaceutical-based dry powder composition that comprises a therapeutically effective amount of drug in combination with a pharmaceutically acceptable carrier.
  • [0051]
    Conditions that may be treated by the compositions of this are described in Table 1.
  • [0052]
    The physiologically effective amount needed to treat a particular condition or disease state will depend on the individual, the condition, length of treatment, the regularity of treatment, the type of drug, and other factors, but can be determined by one of ordinary skill in the medicinal arts.
  • [0053]
    It is presently believed that the effective absorption by a host of dry powder composition according to the present invention results from a rapid dissolution in the ultra-thin (<0.1 μm) fluid layer of the alveolar lining of the lung. The particles of the present invention thus have a mean size which is from 10 to 50 times larger than the lung fluid layer, making it unexpected that the particles are dissolved and the interferon systemically absorbed in a rapid manner for either local lung or systemic treatment. An understanding of the precise mechanism, however, is not necessary for practicing the present invention as described herein.
  • [0054]
    The aerosolized pharmaceutical-based dry powders of this invention are particularly useful in place of parenteral delivery. Thus, the methods and compositions of the present invention will be particularly valuable in chronic treatment protocols where a patient can self-medicate. The patient can achieve a desired dosage by inhaling an appropriate amount of drug, as just described. The efficiency of systemic delivery via the method as just described will typically be in the range from about 15% to 50%.
  • [0055]
    Method for Aerosolizing the Powder.
  • [0056]
    Still another aspect of this invention is a device and method for aerosolizing a pharmaceutical-based dry powder composition that comprises a therapeutically effective amount of drug in combination with a pharmaceutically acceptable carrier, which method comprises dispersing an amount of the dry powder composition in a gas stream to form an aerosol and capturing the aerosol in a chamber having a mouthpiece for subsequent inhalation by a patient.
  • [0057]
    A further detailed description of this method is found in pending U.S. patent application Ser. Nos.: 07/910,048 and 08/207,472, both of which are incorporated herein by reference.
  • [0058]
    Preparing the Compositions.
  • [0059]
    Still another aspect of this invention is a method for preparing a dispersible pharmaceutical-based dry powder composition of this invention that comprises spray drying an aqueous mixture of the drug and a pharmaceutically acceptable carrier under conditions to provide a respirable dry powder composition.
  • [0060]
    Spray drying is a process in which a homogeneous aqueous mixture of drug and the carrier is introduced via a nozzle (e.g., a two fluid nozzle), spinning disc or an equivalent device into a hot gas stream to atomize the solution to form fine droplets. The aqueous mixture may be a solution, suspension, slurry, or the like, but needs to be homogeneous to ensure uniform distribution of the components in the mixture and ultimately the powdered composition. Preferably the aqueous mixture is a solution. The solvent, generally water, rapidly evaporates from the droplets producing a fine dry powder having particles 1 to 5 μm in diameter. Surprisingly, the drug is not degraded when it is exposed to the hot drying gas, and the interferon powders can be prepared having sufficient purity for pharmaceutical use. An acceptable purity is defined as less than 5% degradation products and contaminates, preferably less than 3% and most preferably less than 1%.
  • [0061]
    The spray drying is done under conditions that result in substantially amorphous powder of homogeneous constitution having a particle size that is respirable, a low moisture content and flow characteristics that allow for ready aerosolization. Preferably the particle size of the resulting powder is such that more than about 98% of the mass is in particles having a diameter of about 10 μm or less with about 90% of the mass being in particles having a diameter less than 5 μm. Alternatively, about 95% of the mass will have particles with a diameter of less than 10 μm with about 80% of the mass of the particles having a diameter of less than 5 μm.
  • [0062]
    The solutions may then be sprayed dried in conventional spray drying equipment from commercial suppliers, such as Buchi, Niro, Yamato Chemical Co., Okawara Kakoki Co., and the like, resulting in a substantially amorphous particulate product.
  • [0063]
    For the spraying process, such spraying methods as rotary atomization, pressure atomization and two-fluid atomization can be used. Examples of the devices used in these processes include “Parubisu [phonetic rendering] Mini-Spray GA-32” and “Parubisu Spray Drier DL-41”, manufactured by Yamato Chemical Co., or “Spray Drier CL-8.” “Spray Drier L-8,” “Spray Drier FL-12,” “Spray Drier FL-16” or “Spray Drier FL-20.” manufactured by Okawara Kakoki Co., can be used for the method of spraying using rotary-disk atomizer.
  • [0064]
    While no special restrictions are placed on the nozzle of the atomizer used in the process of spraying, it is recomnmended to use a nozzle which can produce a spray-dry composition with a grain diameter suitable for nasal, pharyngeal or pulmonary administration. For example, nozzle types “1A,” “1,” “2A,” “2,” “3” and the like, manufactured by Yamato Chemical Co., can be used for the above-mentioned spray-drier, manufactured by the same company. In addition, disks type “MC-50,” “MC-65” or “MC-85,” manufactured by Okawara Kakoki Co., can be used as rotary disks of the spray-drier atomizer, manufactured by the same company.
  • [0065]
    While no particular restrictions are placed on the gas used to dry the sprayed material, it is recommended to use air, nitrogen gas or an inert gas. The temperature of the inlet of the gas used to dry the sprayed materials such that it does not cause heat deactivation of the sprayed material. The range of temperatures may vary between about 50° C. to about 200° C., preferably between about 50° C. and 100° C. The temperature of the outlet gas used to dry the sprayed material, may vary between about 0° C. and about 150°, preferably between 0° C. and 90° C., and even more preferably between 0° C. and 60° C. The fact that inlet and outlet temperatures above about 55° C. can be used is surprising in view of the fact that most macromolecule-based drugs deactivate at that temperature, with nearly complete deactivation occurring at about 70° C.
  • [0066]
    The dispersible pharmaceutical-based dry powders of the present invention may optionally be combined with pharmaceutical carriers or excipients which are suitable for respiratory and pulmonary administration. Such carriers may serve simply as bulking agents when it is desired to reduce the interferon concentration in the powder which is being delivered to a patient, but may also serve to enhance the stability of the interferon compositions and to improve the dispersibility of the powder within a powder dispersion device in order to provide more efficient and reproducible delivery of the interferon and to improve handling characteristics of the interferon such as flowability and consistency to facilitate manufacturing and powder filling.
  • [0067]
    Such carrier materials may be combined with the drug prior to spray drying, i.e., by adding the carrier material to the purified bulk solution. In that way, the carrier particles will be formed simultaneously with the drug particles to produce a homogeneous powder. Alternatively, the carriers may be separately prepared in a dry powder, form and combined with the dry powder drug by blending. The powder carriers will usually be crystalline (to avoid water absorption), but might in some cases be amorphous or mixtures of crystalline and amorphous. The size of the carrier particles may be selected to improve the flowability of the drug powder, typically being in the range from 25 μm to 100 μm. A preferred carrier material is crystalline lactose having a size in the above-stated range.
  • [0068]
    Alternatively, dry powder compositions may be prepared by other processes such as lyophilization and jet milling as disclosed in WO 91/16038, the disclosures of which are hereby incorporated by reference.
    TABLE 1
    DRUG INDICATIONS
    SELECTED MACROMOLECULE DRUGS
    FOR SYSTEMIC APPLICATIONS
    Calcitonin Osteoporosis Prophylaxis
    Paget's Disease
    Hypercalcemia
    Erythropoietin (EPO) Anemia
    Factor IX Hemophilia B
    Granulocyte Colony Stimulating Neutropenia
    Factor (G-CSF)
    Granulocyte Macrophage Colony Bone Marrow Engraftment/
    Stimulating Factor (GM-CSF) Transplant Failure
    Growth Hormone Short Stature
    Renal Failure
    Heparin Blood Clotting
    Heparin (Low Molecular Weight) Blood Clotting
    Insulin Type I and Type II Diabetes
    Interferon Alpha Hepatitis B and C
    Hairy Cell Leukemia
    Kaposi's Sarcoma
    Interferon Beta Multiple Sclerosis
    Interferon Gamma Chronic Granulomatous Disease
    Interleukin-2 Renal Cancer
    Luteinizing Hormone Releasing Prostate Cancer
    Hormone (LHRH) Endometriosis
    Somatostatin Analog Gastrointestinal Cancers
    Vasopressin Analog Diabetes Insipidus
    Bed Wetting
    FSH Fertility
    Amylin Type I Diabetes
    Ciliary Neurotrophic Factor Lou Gehrig's Disease
    Growth Hormone Releasing Factor Short Stature
    (GRF)
    Insulin-Like Growth Factor Osteoporosis
    Nutritional Support
    Insulinotropin Type II Diabetes
    Interferon Beta Hepatitis B and C
    Interferon Gamma Rheumatoid Arthritis
    Interleukin-1 Receptor Antagonist Rheumatoid Arthritis
    Interleukin-3 Adjuvant to Chemotherapy
    Interleukin-4 Immunodeficiency Disease
    Interleukin-6 Thrombocytopenia
    Macrophage Colony Stimulating Fungal Disease
    Factor (M-CSF)
    Cancer
    Hypercholesterolemia
    Nerve Growth Factor Peripheral Neuropathies
    Parathyroid Hormone Osteoporosis
    Somatostatin Analog Refractory Diarrheas
    Thymosin Alpha 1 Hepatitis B and C
    IIb/IIIa Inhibitor Unstable Angina
    Alpha-1 Antitrypsin Cystic Fibrosis
    Anti-RSV Antibody Respiratory Syncytial Virus
    Cystic Fibrosis Transmembrane Cystic Fibrosis
    Regulator (CFTR) Gene
    Deoxyribonuclase (DNase) Chronic Bronchitis
    Heparin Asthma
    Bactericidal/Permeability Adult Respiratory Distress Syndrome
    (ARDS)
    Increasing Protein (BPI)
    Anti-CMV Antibody Cytomegalovirus
    Interleukin-1 Receptor Asthma
    SELECTED NON-MACROMOLECULE DRUGS FOR SYSTEMIC
    AND LOCAL LUNG APPLICATIONS
    Pentamidine isethiouate Pneumocystis carini peneumonia
    Albuterol sulfate Broncospasm
    Metaproterenol sulfate Bronchial asthma
    Beclomethasone dipreoionate
    Trimcinoline acetonide
    Budesonide acetonide
    Ipratropium bromide
    Flunisolide
    Cromolyn sodium
    Ergotamine Tartrate Migranes
  • [0069]
    The following exmples are offered by way of illustration and not limitation.
  • EXPERIMENTAL
  • [0070]
    According the the subject invention, the following dispersible dry powder formulations were prepared as described. All compositions produced according to the present invention meet the strict specifications for content and purity required of pharmaceutical products.
  • EXAMPLE I 20.0% Insulin Formulation for Pulmonary Delivery
  • [0071]
    A. Formulation.
  • [0072]
    Bulk crystalline human zinc insulin, was obtained from Eli Lilly and Company, Indianapolis, Ind. A 20% insulin formulation was acheived by combining 1.5 mg insulin per 1.0 mL deionized water with 4.96 mg/mL USP mannitol and 1.04 mg/mL citrate buffer (sodium citrate dihydrate USP and citric acid monohydrate USP) for a total solids concentration of 7.5 mg/mL at pH 6.7±0.3.
  • [0073]
    B. Spray Drying.
  • [0074]
    A dry powder of the 20% insulin formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
    Temperature of aqueous mixture  2-8° C.
    Inlet temperature 120-122° C.
    Feed rate 5.3 mL/min
    Outlet temperature  80-81° C.
  • [0075]
    Once the aqueous mixture was consumed, the outlet temperature was maintained at <80° C. for about 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • [0076]
    C. Characterization.
  • [0077]
    The above 20% insulin dry powder composition contained 66.1 % mannitol and 13.9% citrate. The composition was found to contain 1.1 to 2.0% moisture as measured by a coulombic Karl Fischer method using a Mitsubishi CA-06 Moisture Meter.
  • [0078]
    The particle size distribution of the composition was measured by liquid centrifugal sedimentation in a Horiba CAPA-700 Particle Size Analyzer following dispersion of the powder on Sedisperse A-11 (Micrometrics, Norcross, Ga.) and was determined to be 1.3 μm to 1.5 μm MMD.
  • [0079]
    The delivered dose of the insulin powder composition was measured by collecting the aerosol powder produced by a dry powder dispersion device, similar to devices described in co-pending U.S. application Ser. Nos. 07/910,048; 08/313,707; 08/309,691 and PCT/US92/05621, the disclosures of which are hereby incorporated by reference, on a filter placed over the device mouthpiece. The delivered dose of the insulin powder composition was determined to be 563±16 μg or 60 to 64% of the total powder (5.0 mg) loaded into the device.
  • [0080]
    The aerosol particle size distribution, measured using a cascade impactor (California Measurements IMPAQ-6), was determined to be 2.0 μm MMAD, with 86% to 90% of the particles <5.0 μm in diameter.
  • [0081]
    The insulin content of the powder, measured by reverse phase HPLC (rpHPLC) was determined to be 197 μg/mg powder, accounting for 99% of the expected insulin. No degradation peaks were detected in the chromatogram.
  • EXAMPLE II 5.0% Parathyroid Hormone Formulation for Pulmonary Delivery
  • [0082]
    A. Formulation.
  • [0083]
    Bulk 34 amino acid active fragment of parathyroid hormon, PTH (1-34), was obtained from BACHEM CALIFORNIA. Torrance, Calif. A 5.0% PTH (1-34) formulation was acheived by combining 0.375 mg PTH (1-34) per 1.0 mL deionized water with 6.06 mg/mL mannitol USP and 1.04 mg/mL citrate buffer (sodium citrate dihydrate USP and citric acid monohydrate USP) for a total solids concentration of 7.48 mg/mL at pH 6.3.
  • [0084]
    B. Spray Drying.
  • [0085]
    A dry powder of the 5.0% PTH (1-34) formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
    Temperature of aqueous mixture  2-8° C.
    Inlet temperature 122-124° C.
    Feed rate 5.2 mL/min
    Outlet temperature  73-74° C.
  • [0086]
    Once the aqueous mixture was consumed, the outlet temperature was maintained at <80° C. for about 5 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • [0087]
    C. Characterization.
  • [0088]
    The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
  • [0089]
    The above 5.0% PTH (1-34) dry powder composition contained 81.0% mannitol and 13.9% citrate. The formulation contained 0.5% moisture.
  • [0090]
    The particle size distribution of the composition was determined to be 2.4 μm and 21.71 m MMD in separate measurements.
  • [0091]
    The delivered dose of the PTH (1-34) powder was determined to be 161 μg or 64.5% and 175 μg or 69.2% in separate measurements.
  • [0092]
    The PTH (1-34) content of the powder, measured by rpHPLC was determined to be 48.5 μg/mg powder, accounting for 97% of the expected value. No degradation peaks were detected in the chromatogram.
  • EXAMPLE III 0.7% Interleukin-1 Receptor Formulation for Pulmonary Delivery
  • [0093]
    A. Formulation.
  • [0094]
    Bulk interleukin-1 receptor, IL-1 receptor, was obtained from Immunex Corporation, Seattle, Wash. A 0.7% IL-1 receptor formulation was acheived by combining 0.053 mg IL-1 receptor per 1.0 mL deionized water with 7.07 mg/mL raffinose (Pfanstiehl, Waukegan, Ill.) and 0.373 mg/mL Tris buffer at pH 7.18.
  • [0095]
    B. Spray Drying.
  • [0096]
    A dry powder of the 0.7% IL-1 receptor formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
    Temperature of aqueous mixture  2-8° C.
    Inlet temperature 135-137° C.
    Feed rate 4.9 mL/min
    Outlet temperature  92-93° C.
  • [0097]
    Once the aqueous mixture was consumed, the outlet temperature was maintained at 90° C. for about 15 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • [0098]
    C. Characterization.
  • [0099]
    The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
  • [0100]
    The above 0.7% IL-1 receptor dry powder composition contained 94.3% raffinose and 5.0% Tris. The formulation contained 1.84±0.25% moisture.
  • [0101]
    The particle size distribution of the composition was determined to be 1.95 μm MMD with 100% of the particles <5.0 μm.
  • [0102]
    The delivered dose of the IL-1 receptor powder was determined to be 22.3±2.0 μg or 53.4±4.7%.
  • [0103]
    The aerosol particle size distribution, was determined to be 3.2 μm MMAD, with 77% of the particles <5.0 μm in diameter.
  • [0104]
    The IL-1 receptor content of the powder as measured by rpHPLC was determined to be 8.4 μg/mg, accounting for 120% of the expected IL-1 receptor. No degradation peaks were detected in the chromatogram.
  • EXAMPLE IV 5.0% Interleukin-1 Receptor Formulation for Pulmonary Delivery
  • [0105]
    A. Formulation.
  • [0106]
    Bulk interleukin-1 receptor, IL-1 receptor, was obtained from Immunex Corporation, Seattle, Wash. A 5.0% IL-1 receptor formulation was acheived by combining 0.375 mg IL-1 receptor per 1.0 ml deionized water with 6.77 mg/mL raffinose and 0.351 mg/nmL Tris buffer at pH 7.35.
  • [0107]
    B. Spray Drying.
  • [0108]
    A dry powder of the 5.0% IL-1 receptor formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
    Temperature of aqueous mixture  2-8° C.
    Inlet temperature 138° C.
    Feed rate 4.9 mL/min
    Outlet temperature  91° C.
  • [0109]
    Once the aqueous mixture was consumed, the outlet temperature was maintained at 90° C. for about 15 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • [0110]
    C. Characterization.
  • [0111]
    The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
  • [0112]
    The above 5.0% IL-1 receptor dry powder composition contained 90.3% raffinose and 4.7% Tris. The formulation contained 1.75±0.26% moisture.
  • [0113]
    The particle size distribution of the composition was determined to be 2.74 μm MMD with 97% of the particles <5.0 μm.
  • [0114]
    The delivered dose of the IL-1 receptor powder was determined to be 123.4±24.5 μg or 49.3±9.8 %.
  • [0115]
    The aerosol particle size distribution, was determined to be 4.1 μm MMAD, with 64% of the particles <5.0 μm in diameter.
  • [0116]
    The IL-1 receptor content of the powder as measured by rpHPLC was determined to be 52.7±1.81 μg/mg, accounting for 105% of the expected IL-1 receptor. No degradation peaks were detected in the chromatogram.
  • EXAMPLE V 26Human Calcitonin Formulation for Pulmonary Delivery
  • [0117]
    A. Formulation.
  • [0118]
    Bulk human calcitonin was obtained from Ciba-Geigy. A 26.7% human calcitonin formulation was acheived by combining 1.9 mg human calcitonin per 1.0 mL deionized water with 4.3 mg/mL mannitol and 0.9 mg/mL citrate buffer at pH 3.85.
  • [0119]
    B. Spray Drying.
  • [0120]
    A dry powder of the 26.7% human calcitonin formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
    Temperature of aqueous mixture  4° C.
    Inlet temperature 119° C.
    Feed rate 5.5 mL/min
    Outlet temperature  78° C.
    Atomizer coolant temperature  0-5° C.
    Cyclone coolant temperature  25-30° C.
  • [0121]
    Once the aqueous mixture was consumed, the outlet temperature was maintained at 80° C. for about 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • [0122]
    C. Characterization.
  • [0123]
    The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
  • [0124]
    The above 26.7% human calcitonin dry powder composition contained 60% mannitol and 13.3% citrate. The formulation contained 0.71% moisture.
  • [0125]
    The particle size distribution of the composition was determined to be 1.33±0.63 μm MMD.
  • [0126]
    The delivered dose of the human calcitonin powder was determined to be 76.8±6.7%.
  • [0127]
    The human calcitonin content of the powder as measured by rpHPLC was determined to be 272.0 μg/mg, accounting for 102±1.7% of the expected human calcitonin. No degradation peaks were detected in the chromatogram.
  • EXAMPLE VI 90% Alpha-1 Antitrypsin Formulation For Pulmonary Delivery
  • [0128]
    A. Formulation.
  • [0129]
    Bulk alpha-1 antitrypsin, A1A, was obtained from Armour Pharmaceutical Company, Kankakee. Ill. A 90% A1A formulation was acheived by combining 4.89 mg A1A per 1.0 mL deionized water with 0.54 mg/mL citrate buffer at pH 6.0.
  • [0130]
    B. Spray Drying.
  • [0131]
    A dry powder of the 90% A1A formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
    Temperature of aqueous mixture   4° C.
    Inlet temperature  98-101° C.
    Feed rate 5.0 mL/min
    Outlet temperature  65° C.
    Atomizer coolant temperature   2-8° C.
    Cyclone coolant temperature  30° C.
  • [0132]
    Once the aqueous mixture was consumed, the outlet temperature was maintained at 69° C. for about 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • [0133]
    C. Characterization.
  • [0134]
    The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated othenwise.
  • [0135]
    The above 90% A1A dry powder composition contained 10.0% citrate. The formulation contained 4.79% moisture.
  • [0136]
    The particle size distribution of the composition was determined to be 1.71±0.87 μm MMD.
  • [0137]
    The delivered dose of the 90% A1A powder was determined to be 67.0±5.0%.
  • [0138]
    The aerosol particle size distribution, was determined to be 1.0 μm MMAD, with 90% of the particles <5.0 μm in diameter.
  • [0139]
    The A1A content of the powder as measured by rpHPLC was determined to be 80% of the expected value. No degradation peaks were detected in the chromatogram. The activity after spray drying was determined to be 74±1%
  • EXAMPLE VII 0.3% Beta Interferon Formulation for Pulmonary Delivery Containing Human Serum Albumin
  • [0140]
    A. Formulation.
  • [0141]
    Bulk beta interferon, IFN-β, was obtained from Toray Industries, Inc., Tokyo, Japan. A 0.3% IFN-β formulation was acheived by combining 0.025 mg IFN-β per 1.0 mL deionized water with 5.54 mg/mL human serum albuman (HSA), 2.3 mg/mL citrate buffer and 0.345 mg/mL of NaCl at pH 4.5.
  • [0142]
    B. Spray Drying.
  • [0143]
    A dry powder of the 0.3% IFN-β formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
    Temperature of aqueous mixture   2-8° C.
    Inlet temperature  93° C.
    Feed rate 2.7 mL/min
    Outlet temperature  62° C.
  • [0144]
    C. Characterization.
  • [0145]
    The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
  • [0146]
    The above 0.3% IFN-β dry powder composition contained 66.0% HSA, 27.4% citrate, 4.1% NaCl. The formulation contained 4.22% moisture.
  • [0147]
    The particie size distribution of the composition was determined to be 1.62 μm MMD with 94.8% of the particles <5 μm.
  • [0148]
    The delivered dose of the 0.3% IFN-β powder was determined to be 9.9 μg/mg or 66.0±4.0%.
  • [0149]
    The aerosol particle size distribution, was determined to be 2.0 μm MMAD, with 85% of the particles <5.0 μm in diameter.
  • [0150]
    The IFN-β activity of the powder as measured by IFN-β enzyme immunoassay (Toray-Fuji Bionics) and was determined to be 109±8% of the expected activity.
  • EXAMPLE VIII 0.3% Beta Interferon Formulation for Pulmonary Delivery Containing Raffinose
  • [0151]
    A. Formulation.
  • [0152]
    Bulk beta interferon, IFN-β, was obtained from Toray Industries, Inc., Tokyo, Japan. A 0.3% IFN-β formulation was acheived by combining 0.025 mg IFN-β per 1.0 mL deionized water with 4.7 mg/mnL raffinose, 1.0 mg/mL human serum albuman (HSA), 2.3 mg/mL citrate buffer and 0.3 mg/mL of NaCl at pH 4.5.
  • [0153]
    B. Spray Drying.
  • [0154]
    A dry powder of the 0.3% IFN-β formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
    Temperature of aqueous mixture  8° C.
    Inlet temperature 145° C.
    Feed rate 5.0 mL/min
    Outlet temperature  87° C.
  • [0155]
    Once the aqueous mixture was consumed, the outlet temperature was maintained at 97° C. for about 5 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • [0156]
    C. Characterization.
  • [0157]
    The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
  • [0158]
    The above 0.3% IFN-β dry powder composition contained 56.4% raffinose, 11.9% HSA, 27.4% citrate, 3.5% NaCl. The formulation contained 0.69% moisture.
  • [0159]
    The particle size distribution of the composition was determined to be 2.06 μm MMD with 88.9% of the particles <5μm.
  • [0160]
    The delivered dose of the 0.3% IFN-β powder was determined to be 10.2 μg/mg or 68.0±2.0%.
  • [0161]
    The aerosol particle size distribution, was determined to be 2.5 μm MMAD, with 84% of the particles <5.0 μm in diameter.
  • [0162]
    The IFN-β activity of the powder as measured by IFN-β enzyme immunoassay (Toray-Fuji Bionics) and was determined to be 109±8% of the expected activity.
  • EXAMPLE IX 93% Low Molecular Weight Heparin Formulation for Pulmonary Delivery
  • [0163]
    A. Formulation.
  • [0164]
    Bulk low molecular weight heparin sodium salt (Av. Mol. Wt.: Approx. 6000) from porcine intestinal mucosa, heparin (LMW), was obtained from Sigma Chemical, St. Louis, Mo.. A 93% heparin (LMW) formulation was acheived by combining 6.9 mg heparin (LMW) per 1.0 mL deionized water with 0.5 mg/mL HSA at pH 6.9.
  • [0165]
    B. Spray Drying.
  • [0166]
    A dry powder of the 93% heparin (LMW) formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
    Temperature of aqueous mixture  2-8° C.
    Inlet temperature 140° C.
    Feed rate 3.8 mL/min
    Outlet temperature  85° C.
    Atomizer coolant temperature  2-8° C.
    Cyclone coolant temperature  20° C.
  • [0167]
    Once the aqueous mixture was consumed, the outlet temperature was maintained at 80° C. for about 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • [0168]
    C. Characterization.
  • [0169]
    The following characterization or the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
  • [0170]
    The above 93% heparin (LMW) dry powder composition contained 7.0% HSA.
  • [0171]
    The delivered dose of the 93% heparin (LMW) powder was determined to be 60.0±1.0%.
  • [0172]
    The aerosol particle size distribution, was determined to be 3.5 μm MMAD, with 70% of the particles <5.0 μm in diameter.
  • EXAMPLE X 97% Unfractionated Heparin Formulation for Pulmonary Delivery
  • [0173]
    A. Formulation.
  • [0174]
    Bulk unfractionated heparin sodium salt from porcine intestinal mucosa, heparin, was obtained from Sigma Chemical, St. Louis, Mo. A 97% heparin formulation was acheived by combining 7.0 mg heparin per 1.0 mL deionized water with 0.25 mg/mL HSA at pH 6.55.
  • [0175]
    B. Spray Drying.
  • [0176]
    A dry powder of the 97% heparin formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
    Temperature of aqueous mixture 2-8° C.
    Inlet temperature 150° C.
    Feed rate 4.0 mL/min
    Outlet temperature 85° C.
    Atomizer coolant temperature 2-8° C.
    Cyclone coolant temperature 20° C.
  • [0177]
    Once the aqueous mixture was consumed, the outlet temperature was maintained at 80° C. for about 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • [0178]
    C. Characterization.
  • [0179]
    The following characterization of the dry powder formulation described above was carried out usine the methods described in Example I unless indicated otherwise.
  • [0180]
    The above 97% heparin dry powder composition contained 3.0% HSA. The formulation contained 5.11% moisture.
  • [0181]
    The particle size distribution of the composition was determined to be 2.0 to 2.5 μm MMD.
  • [0182]
    The delivered dose of the 97% heparin powder was determined to be 79.0±6.0%.
  • [0183]
    The aerosol particle size distribution, was determined to be 3.2 μm MMAD, with 70% of the particles <5.0 μm in diameter.
  • EXAMPLE XI Lipid Vector Gene Formulation for Pulmonary Delivery
  • [0184]
    A. Formulation.
  • [0185]
    Bulk pCMVβ DNA:Lipid vector as described in U.S. application Ser. No.: 08/______ (attorney docket no. 15225-000410 filed Apr. 14, 1995 entitled COMPOSITIONS AND METHODS FOR NUCLEIC ACID DELIVERY TO THE LUNG, the disclosures of which are hereby incorporated by reference. Was obtained from Genzyme Corporation, Cambridge, Mass. A 0.71% DNA:Lipid vector formulation was acheived by combining 0.005:0.03 mg DNA:Lipid vector per 1.0 mL deionized water with 5.3 mg/mL glycine (J. T. Baker) 0.3 mg/mL HSA at pH 6.4.
  • [0186]
    B. Spray Drying.
  • [0187]
    A dry powder of the DNA:Lipid vector formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
    Temperature of aqueous mixture 2-8° C.
    Inlet temperature 120° C.
    Feed rate 3.8 mL/min
    Outlet temperature 71° C.
    Atomizer coolant temperature 2-8° C.
    Cyclone coolant temperature 2-8° C.
  • [0188]
    Once the aqueous mixture was consumed, the outlet temperature was maintained at 65° C. for about 5 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • [0189]
    C. Characterization.
  • [0190]
    The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
  • [0191]
    The above 0.71% DNA:Lipid vector dry powder composition contained 93.97% glycine, and 5.32% HSA.
  • [0192]
    The particle size distribution of the composition was determined to be 2.0 μm MMD.
  • [0193]
    The delivered dose of the 97% heparin (HMW) powder was determined to be 64.0±1.0%.
  • [0194]
    The aerosol particle size distribution, was determined to be 2.4 μm MMAD, with 75% of the particles <5.0 μm in diameter.
  • [0195]
    Activity after spray drying was determined to be 160% of the expected value.
  • EXAMPLE XII Adenoviral Vector Gene Formulation for Pulmonary Delivery
  • [0196]
    A. Formulation.
  • [0197]
    Bulk pCMVβ DNA:Adenovirous vector as described in U.S. application Ser. No.: 08/______ (attorney docket no. 15225-000410) filed Apr. 14, 1995 entitled COMPOSITIONS AND METHODS FOR NUCLEIC ACID DELIVERY TO THE LUNG, the disclosures of which are hereby incorporated by reference, was obtained from Genzyme Corporation, Cambridge, Mass. A DNA:adenovirous vector formulation was acheived by combining 108 PFU/mL DNA:Lipid vector per 1.0 mL deionized water with 6.1 mg/mL glycine J. T. Baker) 2.5 mg/mL HSA, 1.9 mg/mL phosphate buffer at pH 7.4.
  • [0198]
    B. Spray Drying.
  • [0199]
    A dry powder of the DNA:Lipid vector formulation described above was produced by spray drying the aqueous mixture using a Buchi Laboratory Spray Dryer under the following conditions:
    Temperature of aqueous mixture 2-8° C.
    Inlet temperature 105° C.
    Feed rate 2.9 mL/min
    Outlet temperature 72° C.
    Atomizer coolant temperature 2-8° C.
    Cyclone coolant temperature 20° C.
  • [0200]
    Once the aqueous mixture was consumed, the outlet temperature was maintained at 70° C. for about 10 minutes by slowly decreasing the inlet temperature to provide a secondary drying.
  • [0201]
    C. Characterization.
  • [0202]
    The following characterization of the dry powder formulation described above was carried out using the methods described in Example I unless indicated otherwise.
  • [0203]
    The above DNA:adenovirous vector dry powder composition contained 58% glycine, and 24% HSA and 18% phosphate buffer.
  • [0204]
    The particle size distribution of the composition was determined to be 2.3 μm MMD.
  • [0205]
    The delivered dose of the 97% heparin (HMW) powder was determined to be 51.0±1.0%.
  • [0206]
    The aerosol particle size distribution, was determined to be 1.8 μm MMAD, with 80% of the particles <5.0 μm in diameter.
  • [0207]
    Activity after spray drying was determined to be 76% of the expected value.
  • [0208]
    All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
  • [0209]
    The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2598525 *Apr 8, 1950May 27, 1952E & J Mfg CoAutomatic positive pressure breathing machine
US3300474 *Feb 12, 1964Jan 24, 1967Pharmacia AbSucrose ether copolymerizates
US3314803 *Jan 26, 1966Apr 18, 1967Gen Foods CorpMannitol fixed flavor and method of making same
US3362405 *Apr 6, 1964Jan 9, 1968Hamilton O. HazelMethod and apparatus for admixing gas with solid particles
US3425600 *Aug 11, 1966Feb 4, 1969Abplanalp Robert HPressurized powder dispensing device
US3554768 *Aug 1, 1967Jan 12, 1971Gen Foods CorpCarbohydrate fixed acetaldehyde
US3555717 *Oct 24, 1968Jan 19, 1971Victor Comptometer CorpArtificial fishing lure
US3557717 *May 17, 1968Jan 26, 1971Gen Mills IncProcess for making candy floss
US3632357 *Jul 29, 1969Jan 4, 1972Standard Brands IncMethod of producing hard candy
US3655442 *Aug 27, 1969Apr 11, 1972California & Hawaiian SugarMethod of making sugar and sugar products
US3666496 *Sep 3, 1969May 30, 1972Firmenich IncWater soluble,powdered,terpene-containing flavors
US3937668 *Nov 6, 1972Feb 10, 1976Ilse ZolleMethod for incorporating substances into protein microspheres
US3948263 *Aug 14, 1974Apr 6, 1976Minnesota Mining And Manufacturing CompanyBallistic animal implant
US4069819 *Aug 5, 1976Jan 24, 1978Societa Farmaceutici S.P.A.Inhalation device
US4244949 *Apr 6, 1978Jan 13, 1981The Population Council, Inc.Manufacture of long term contraceptive implant
US4249526 *Apr 12, 1979Feb 10, 1981Fisons LimitedInhalation device
US4253468 *Aug 14, 1978Mar 3, 1981Steven LehmbeckNebulizer attachment
US4326524 *Sep 30, 1980Apr 27, 1982Minnesota Mining And Manufacturing CompanySolid dose ballistic projectile
US4327076 *Nov 17, 1980Apr 27, 1982Life Savers, Inc.Compressed chewable antacid tablet and method for forming same
US4327077 *May 29, 1981Apr 27, 1982Life Savers, Inc.Compressed chewable antacid tablet and method for forming same
US4371557 *Jan 21, 1981Feb 1, 1983General Foods CorporationMaintenance of protein quality in foods containing reducing sugars
US4503035 *Feb 14, 1983Mar 5, 1985Hoffmann-La Roche Inc.Protein purification process and product
US4649911 *Mar 7, 1986Mar 17, 1987Baylor College Of MedicineSmall particle aerosol generator for treatment of respiratory disease including the lungs
US4659696 *Apr 22, 1983Apr 21, 1987Takeda Chemical Industries, Ltd.Pharmaceutical composition and its nasal or vaginal use
US4719762 *Nov 18, 1986Jan 19, 1988Toshiba Heating Appliances Co., Ltd.Stored ice detecting device in ice making apparatus
US4721709 *Aug 4, 1984Jan 26, 1988Pyare SethNovel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
US4739754 *May 6, 1986Apr 26, 1988Shaner William TSuction resistant inhalator
US4806343 *Mar 13, 1986Feb 21, 1989University Of Southwestern LouisianaCryogenic protectant for proteins
US4807814 *Jan 3, 1986Feb 28, 1989Saint Gobain VitragePneumatic powder ejector
US4811731 *Jul 29, 1986Mar 14, 1989Glaxo Group LimitedDevices for administering medicaments to patients
US4812444 *Dec 16, 1986Mar 14, 1989Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoDehydration of hydrous matter using anhydrous glycosylfructose
US4814436 *Dec 8, 1986Mar 21, 1989Ss Pharmaceutical Co., Ltd.Derivative of α, α-trehalose and a process for preparing the same
US4819629 *Oct 20, 1987Apr 11, 1989Siemens AktiengesellschaftMethod and apparatus for delivering aerosol to the airways and/or lungs of a patient
US4820534 *Jun 10, 1988Apr 11, 1989General Foods CorporationFixation of volatiles in extruded glass substrates
US4823784 *Nov 2, 1987Apr 25, 1989Cadema Medical Products, Inc.Aerosol inhalation apparatus
US4824938 *Aug 31, 1987Apr 25, 1989Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoWater-soluble dry solid containing proteinaceous bioactive substance
US4891319 *Jul 9, 1986Jan 2, 1990Quadrant Bioresources LimitedProtection of proteins and the like
US4895719 *Mar 6, 1987Jan 23, 1990Liposome Technology, Inc.Method and apparatus for administering dehydrated liposomes by inhalation
US4897353 *Oct 30, 1986Jan 30, 1990University Of Southwestern LouisianaCryogenic protection of phosphofructokinase using amino acids and zinc ions
US4906463 *Apr 8, 1988Mar 6, 1990Cygnus Research CorporationTransdermal drug-delivery composition
US4907583 *Dec 16, 1988Mar 13, 1990Aktiebolaget DracoDevice in powder inhalators
US4919962 *Sep 22, 1988Apr 24, 1990General Foods CorporationCoffee flakes and process
US4984158 *Oct 14, 1988Jan 8, 1991Hillsman DeanMetered dose inhaler biofeedback training and evaluation system
US4995385 *Feb 23, 1990Feb 26, 1991Phidea S.P.A.Inhaler with regular complete emptying of the capsule
US5011678 *Feb 1, 1989Apr 30, 1991California Biotechnology Inc.Composition and method for administration of pharmaceutically active substances
US5081228 *Oct 13, 1988Jan 14, 1992Immunex CorporationInterleukin-1 receptors
US5089181 *Oct 30, 1989Feb 18, 1992Vestar, Inc.Method of dehydrating vesicle preparations for long term storage
US5093316 *Oct 2, 1990Mar 3, 1992John LezdeyTreatment of inflammation
US5098893 *Feb 12, 1990Mar 24, 1992Pafra LimitedStorage of materials
US5099833 *Feb 19, 1991Mar 31, 1992Baxter International Inc.High efficiency nebulizer having a flexible reservoir
US5180812 *Dec 21, 1989Jan 19, 1993Immunex CorporationSoluble human interleukin-1 receptors, compositions and method of use
US5186164 *Mar 15, 1991Feb 16, 1993Puthalath RaghuprasadMist inhaler
US5192528 *Dec 1, 1989Mar 9, 1993Liposome Technology, Inc.Corticosteroid inhalation treatment method
US5200399 *Apr 1, 1991Apr 6, 1993Boyce Thompson Institute For Plant Research, Inc.Method of protecting biological materials from destructive reactions in the dry state
US5202333 *May 22, 1991Apr 13, 1993Syntex (U.S.A.) Inc.Tricyclic 5-HT3 receptor antagonists
US5204108 *Oct 10, 1988Apr 20, 1993Danbiosyst Uk Ltd.Transmucosal formulations of low molecular weight peptide drugs
US5206200 *Apr 22, 1991Apr 27, 1993W. R. Grace & Co.-Conn.Tin catalysts for hydrolysis of latent amine curing agents
US5284656 *Sep 29, 1992Feb 8, 1994Amgen Inc.Pulmonary administration of granulocyte colony stimulating factor
US5290765 *Feb 11, 1992Mar 1, 1994Boyce Thompson Institute For Plant Research, Inc.Method of protecting biological materials from destructive reactions in the dry state
US5295479 *Apr 15, 1991Mar 22, 1994Leiras OyDevice intended for measuring a dose of powdered medicament for inhalation
US5302581 *Jan 22, 1992Apr 12, 1994Abbott LaboratoriesPulmonary surfactant protein fragments
US5306506 *Jul 4, 1991Apr 26, 1994Eurand International S.P.A.Pharmaceutical composition for rapid suspension in water
US5380473 *Oct 23, 1992Jan 10, 1995Fuisz Technologies Ltd.Process for making shearform matrix
US5384133 *Jun 29, 1993Jan 24, 1995Innovata Biomed LimitedPharmaceutical formulations comprising microcapsules
US5387431 *Mar 5, 1992Feb 7, 1995Fuisz Technologies Ltd.Saccharide-based matrix
US5403861 *Feb 10, 1992Apr 4, 1995Cambridge Neuroscience, Inc.Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
US5404871 *Mar 5, 1991Apr 11, 1995AradigmDelivery of aerosol medications for inspiration
US5482927 *Feb 23, 1994Jan 9, 1996Massachusetts Institute Of TechnologyControlled released microparticulate delivery system for proteins
US5488062 *Aug 9, 1994Jan 30, 1996Sterling Winthrop Inc.2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5506203 *Jun 23, 1994Apr 9, 1996Ab AstraSystemic administration of a therapeutic preparation
US5512547 *Oct 13, 1994Apr 30, 1996Wisconsin Alumni Research FoundationPharmaceutical composition of botulinum neurotoxin and method of preparation
US5591453 *Jun 7, 1995Jan 7, 1997The Trustees Of The University Of PennsylvaniaIncorporation of biologically active molecules into bioactive glasses
US5618786 *Mar 9, 1994Apr 8, 1997Cooper Laboratories, Inc.Aerosolization of protein therapeutic agent
US5621094 *Jun 8, 1994Apr 15, 1997Quadrant Holdings Cambridge LimitedMethod of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol
US5705482 *Jan 13, 1995Jan 6, 1998Novo Nordisk A/SPharmaceutical formulation
US5707644 *Dec 20, 1994Jan 13, 1998Danbiosyst Uk LimitedSmall particle compositions for intranasal drug delivery
US5728574 *Jul 19, 1994Mar 17, 1998Zeneca LimitedViability of bacterial dried cells
US5733555 *Apr 25, 1996Mar 31, 1998American Home Products CorporationModified live BRSV vaccine
US5855913 *Jan 16, 1997Jan 5, 1999Massachusetts Instite Of TechnologyParticles incorporating surfactants for pulmonary drug delivery
US5891873 *Apr 13, 1995Apr 6, 1999Quadrant Holdings Cambridge LimitedUse of maillard reaction inhibitors for the treatment of amyloidosis-based disease
US6013638 *Dec 13, 1993Jan 11, 2000The United States Of America As Represented By The Department Of Health And Human ServicesAdenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US6019968 *Oct 16, 1997Feb 1, 2000Inhale Therapeutic Systems, Inc.Dispersible antibody compositions and methods for their preparation and use
US6034080 *Dec 4, 1998Mar 7, 2000Quadrant Holdings Cambridge LimitedUse of Maillard reaction inhibitors for the treatment of amyloidosis-based disease
US6051256 *May 8, 1996Apr 18, 2000Inhale Therapeutic SystemsDispersible macromolecule compositions and methods for their preparation and use
US6187344 *Jul 31, 1997Feb 13, 2001Inhale Therapeutic SystemsPowdered pharmaceutical formulations having improved dispersibility
US6190859 *Apr 17, 1995Feb 20, 2001The United States Of America As Represented By The Secretary Of The ArmyMethod and kit for detection of dengue virus
US6358530 *Sep 25, 2000Mar 19, 2002Inhale Therapeutic Systems, Inc.Powdered pharmaceutical formulations having improved dispersibility
US6365190 *Mar 17, 2000Apr 2, 2002Inhale Therapeutic Systems, Inc.Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6372258 *Nov 22, 1999Apr 16, 2002Inhale Therapeutic SystemsMethods of spray-drying a drug and a hydrophobic amino acid
US6503411 *May 22, 2000Jan 7, 2003Inhale Therapeutic Systems, Inc.Stable compositions
US6509006 *Oct 26, 1999Jan 21, 2003Inhale Therapeutic Systems, Inc.Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6514496 *Mar 21, 2000Feb 4, 2003Inhale Therapeutic Systems, Inc.Dispersible antibody compositions and methods for their preparation and use
US6518239 *Apr 13, 2000Feb 11, 2003Inhale Therapeutic Systems, Inc.Dry powder compositions having improved dispersivity
US6681767 *May 1, 2000Jan 27, 2004Nektar TherapeuticsMethod and device for delivering aerosolized medicaments
US6685967 *Jun 17, 1996Feb 3, 2004Nektar TherapeuticsMethods and compositions for pulmonary delivery of insulin
US20030035778 *Sep 17, 2002Feb 20, 2003Robert PlatzMethods and compositions for the dry powder formulation of interferon
US20030068279 *Sep 13, 2002Apr 10, 2003Platz Robert M.Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments
US20030072718 *Sep 18, 2002Apr 17, 2003Platz Robert M.Methods and compositions for the dry powder formulation of interferons
US20040052825 *Aug 29, 2003Mar 18, 2004Roser Bruce J.Solid dose delivery vehicle and methods of making same
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7560444Oct 1, 2004Jul 14, 2009Momenta Pharmaceuticals, Inc.Polysaccharides for pulmonary delivery of active agents
US7709461Oct 18, 2001May 4, 2010Massachusetts Institute Of TechnologyMethods and products related to pulmonary delivery of polysaccharides
US7744925May 20, 2005Jun 29, 2010Quadrant Drug Delivery LimitedSolid dose delivery vehicle and methods of making same
US7780991May 20, 2005Aug 24, 2010Quadrant Drug Delivery LimitedSolid dose delivery vehicle and methods of making same
US7785631May 20, 2005Aug 31, 2010Quadrant Drug Delivery LimitedSolid dose delivery vehicle and methods of making same
US7928089Sep 15, 2004Apr 19, 2011Vectura LimitedMucoactive agents for treating a pulmonary disease
US8246934Sep 3, 2010Aug 21, 2012Novartis AgRespiratory dispersion for metered dose inhalers comprising perforated microstructures
US8322046 *Mar 18, 2008Dec 4, 2012Zhaolin WangPowder formation by atmospheric spray-freeze drying
US8404217Jul 22, 2005Mar 26, 2013Novartis AgFormulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US8709484Oct 24, 2008Apr 29, 2014Novartis AgPhospholipid-based powders for drug delivery
US8715623Oct 31, 2007May 6, 2014Novartis AgPulmonary delivery of aminoglycoside
US8877162Dec 6, 2012Nov 4, 2014Novartis AgStable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9421166Apr 8, 2014Aug 23, 2016Novartis AgPulmonary delivery of aminoglycoside
US9439862Apr 2, 2014Sep 13, 2016Novartis AgPhospholipid-based powders for drug delivery
US9554993May 5, 2010Jan 31, 2017Novartis AgPulmonary delivery particles comprising an active agent
US20020128225 *Oct 18, 2001Sep 12, 2002Massachusetts Institute Of TechnologyMethods and products related to pulmonary delivery of polysaccharides
US20030035778 *Sep 17, 2002Feb 20, 2003Robert PlatzMethods and compositions for the dry powder formulation of interferon
US20030072718 *Sep 18, 2002Apr 17, 2003Platz Robert M.Methods and compositions for the dry powder formulation of interferons
US20030113273 *Sep 18, 2002Jun 19, 2003Patton John S.Methods and compositions for pulmonary delivery of insulin
US20030171282 *Sep 18, 2002Sep 11, 2003Patton John S.Pulmonary delivery of active fragments of parathyroid hormone
US20040087543 *Apr 25, 2003May 6, 2004Zachary ShriverMethods and products for mucosal delivery
US20050207988 *Oct 1, 2004Sep 22, 2005Thomas RichardsonPolysaccharides for pulmonary delivery of active agents
US20050276759 *May 20, 2005Dec 15, 2005Roser Bruce JSolid dose delivery vehicle and methods of making same
US20050276846 *May 20, 2005Dec 15, 2005Roser Bruce JSolid dose delivery vehicle and methods of making same
US20070037776 *Aug 8, 2006Feb 15, 2007Tom RichardsonPolysaccharides for delivery of active agents
US20080075782 *Oct 30, 2007Mar 27, 2008Patton John SPulmonary delivery of active fragments parathyroid hormone
US20090203576 *Mar 3, 2009Aug 13, 2009Patton John SMethods and compositons for pulmonary delivery of insulin
US20110217339 *Mar 8, 2011Sep 8, 2011Vectura LimitedMucoactive agents for treating a pulmonary disease
Classifications
U.S. Classification424/46
International ClassificationA61K9/16, A61K9/00, A61K38/28, A61K38/21, A61M15/00
Cooperative ClassificationA61M15/0051, A61K9/1658, A61K9/1617, B82Y5/00, A61K38/215, A61M2205/073, A61K47/48053, A61K38/28, A61K9/1694, A61M15/0033, A61K38/21, A61M15/0086, A61K9/0075, A61M2202/064, A61M2205/0233, A61K9/1652, A61K9/1611, A61K9/1623, A61M15/0045
European ClassificationB82Y5/00, A61K47/48H4F4, A61K9/00M20B3, A61K9/16H4B, A61K38/21, A61K38/21B, A61K9/16H6H, A61M15/00C2, A61K9/16H4, A61K38/28, A61K9/16P4, A61K9/16H6F, A61K9/16H2
Legal Events
DateCodeEventDescription
Feb 25, 2003ASAssignment
Owner name: NEKTAR THERAPEUTICS, CALIFORNIA
Free format text: CHANGE OF NAME;ASSIGNOR:INHALE THERAPEUTIC SYSTEMS, INC.;REEL/FRAME:013525/0753
Effective date: 20030113
Jan 7, 2009ASAssignment
Owner name: NOVARTIS PHARMA AG, SWITZERLAND
Free format text: ASSIGNMENT OF PATENT RIGHTS;ASSIGNOR:NEKTAR THERAPEUTICS;REEL/FRAME:022071/0001
Effective date: 20081231
Owner name: NOVARTIS PHARMA AG,SWITZERLAND
Free format text: ASSIGNMENT OF PATENT RIGHTS;ASSIGNOR:NEKTAR THERAPEUTICS;REEL/FRAME:022071/0001
Effective date: 20081231